5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 3.98▲ | 3.97▲ | 3.97▲ | 4.05▼ | 4.24▼ |
MA10 | 3.97▲ | 3.98▲ | 3.99▲ | 4.16▼ | 4.38▼ |
MA20 | 4.01▼ | 4.04▼ | 4.05▼ | 4.29▼ | 4.33▼ |
MA50 | 4.06▼ | 4.11▼ | 4.14▼ | 4.38▼ | 5.70▼ |
MA100 | 4.15▼ | 4.25▼ | 4.28▼ | 4.43▼ | 6.99▼ |
MA200 | 4.28▼ | 4.39▼ | 4.37▼ | 5.57▼ | 42.98▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.005▲ | -0.002▼ | -0.001▼ | -0.039▼ | 0.056▲ |
RSI | 47.492▼ | 44.544▼ | 43.278▼ | 38.911▼ | 35.521▼ |
STOCH | 54.968 | 17.500▼ | 16.420▼ | 13.279▼ | 36.878 |
WILL %R | -40.000 | -66.667 | -66.667 | -89.158▼ | -84.322▼ |
CCI | 72.055 | -1.111 | -14.506 | -115.786▼ | -103.857▼ |
Wednesday, July 16, 2025 04:54 AM
KZR Price Action: Kezar Life Sciences shares were down 9.09% at $4.20 at the time of publication Wednesday, according to Benzinga Pro. Read Next: ...
|
Monday, July 14, 2025 05:00 PM
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that ...
|
Tuesday, July 01, 2025 09:08 AM
Nasdaq handily beat the New York Stock Exchange in stock market listings during the first half of 2025, buoyed by blockbuster initial public offerings of big names like CoreWeave and Chime and a ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
08/08/25 | 4.00 | 4.0226 | 3.9307 | 4.005 | 23,250 |
07/08/25 | 4.10 | 4.175 | 3.98 | 3.98 | 31,285 |
06/08/25 | 4.05 | 4.1924 | 4.0002 | 4.10 | 38,999 |
05/08/25 | 4.06 | 4.23 | 4.05 | 4.07 | 84,904 |
04/08/25 | 4.02 | 4.18 | 3.975 | 4.10 | 42,227 |
01/08/25 | 4.21 | 4.234 | 4.00 | 4.05 | 67,095 |
31/07/25 | 4.30 | 4.375 | 4.25 | 4.27 | 37,004 |
30/07/25 | 4.30 | 4.36 | 4.29 | 4.29 | 9,424 |
29/07/25 | 4.35 | 4.41 | 4.2499 | 4.33 | 48,253 |
28/07/25 | 4.30 | 4.44 | 4.30 | 4.36 | 20,003 |
|
|
||||
|
|
||||
|
|